ViroPharma (Nasdaq: VPHM ) reported earnings on Feb. 27. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), ViroPharma beat expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue dropped significantly. Non-GAAP earnings per share dropped significantly. GAAP earnings per share contracted to a loss.
Margins contracted across the board.
Revenue details
ViroPharma reported revenue of $106.5 million. The 13 analysts polled by S&P Capital IQ hoped for net sales of $102.8 million on the same basis. GAAP reported sales were 27% lower than the prior-year quarter's $145.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
EPS came in at $0.10. The seven earnings estimates compiled by S&P Capital IQ anticipated $0.12 per share. Non-GAAP EPS of $0.10 for Q4 were 81% lower than the prior-year quarter's $0.52 per share. GAAP EPS were -$0.06 for Q4 against $0.65 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Margin details
For the quarter, gross margin was 74.8%, much worse than the prior-year quarter. Operating margin was -1.9%, much worse than the prior-year quarter. Net margin was -3.7%, much worse than the prior-year quarter.
Looking ahead
Next quarter's average estimate for revenue is $107.4 million. On the bottom line, the average EPS estimate is $0.15.
Next year's average estimate for revenue is $466.5 million. The average EPS estimate is $0.72.
Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,195 members out of 1,236 rating the stock outperform, and 41 members rating it underperform. Among 325 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 317 give ViroPharma a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ViroPharma is outperform, with an average price target of $32.81.
- Add ViroPharma to My Watchlist.
No comments:
Post a Comment